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Chemistry, University of Cologne, Cologne, GermanyObjective. To compare the prevalence of APC-resistance (APC-R) in patients with peripheral vascular disease and the
general population.
Design. Prospective cohort examination.
Materials and methods. Three hundred and eleven patients (group A) suffering from arterial occlusive disease or an
abdominal aortic aneurysm were prospectively screened for APC-R. There were 228 men and 83 women with a mean age of
65 years (20–88 years). Two hundred and sixty patients underwent an open surgical or interventional procedure. A total of
306 patients were followed clinically for an average of 8 months (1–31 months). Two hundred and seven healthy volunteers
(group B) served as a control group.
Results. The prevalence of a functional APC-R was 11% (33/311) and 8% in groups A and B, respectively, (pZ0.272).
APC-R did not occur more frequently among patients who were treated primarily for a bypass occlusion (3/21 vs 30/290)
(pZ0.476). None of five patients who had a postinterventional graft or vessel occlusion (1.9%) had an APC-R. Sixteen
patients (5%) experienced an arterial occlusion during follow-up of which two had APC-R.
Conclusions. Previously published increased prevalence rates of APC-R in patients with arterial disorders could not be
confirmed in this study. A firm association between the presence of APC-R and previous bypass occlusion or postoperative
failure of the vascular reconstruction could not be demonstrated.Keywords: Arterial diseases; APC-resistance; Vascular surgery.Introduction
According to Virchow’s triad changes of blood flow, a
diseased vessel wall and alterations of the blood
contents favour thrombosis. Deficiencies in physio-
logical inhibitors of coagulation like antithrombin III,
protein C and S thus, promote thrombus formation.
Resistance to activated protein C (APC-R) is the
commonest inherited coagulation disorder associated
with deep vein thrombosis,1–3 however, the associ-
ation with arterial thrombosis is less clear.4–6 A higher
prevalence of APC-R could be shown among younger
individuals having a stroke or myocardial infarction
compared to the normal population.7–10 The impact of
APC-R on postoperative failure of vascular reconstruc-
tions remains unclear.11
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prevalence in the normal population,12 which varies
between 3 and 8%. In contrast to the Caucasian
population, APC-R is rarely seen or even unknown
in the native people in East Asia (Indonesia, Japan,
China), Africa, Australia or South America. The aim of
this study was to assess the relationship between APC-
R and arterial disease in a population in Western
Germany.13Materials and Methods
From January until December 2000, 311 consecutive
patients (228 men, 83 women) with an average age of
65 years ranging from 20 to 88 years were electively
treated in our department for either peripheral arterial
occlusive disease (PAOD, nZ240) or abdominal aortic
aneurysm (AAA, nZ71). The patients were prospec-
tively screened for APC-R using a functional testEur J Vasc Endovasc Surg 30, 160–163 (2005)
doi:10.1016/j.ejvs.2005.03.008, available online at http://www.sciencedirect.com onved.
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ance V, Chromogenix, Italy). The standard PTT time
(PTT1) is compared to a second measurement in which
APC is added leading to inactivation of factor Va and a
prolongation of PTT (PTT2). The ratio of PTT2/PTT1
will, therefore, be lower than the reference range in the
case of APC-R. If the functional test showed a
pathological result (APC-ratio !2.1) Factor V-Leiden
mutation was sort using PCR (LightCyclerw, Roche
Diagnostics, Germany).
After taking the medical history, the patients
underwent a complete physical examination including
a detailed vascular assessment and the ankle-brachial
index (ABI) measurement. A detailed description of
the interventional procedures is given in Table 1. The
patients were screened for the presence of risk factors
including immobilisation, trauma, obesity, defined as
a body mass index O25 kg/m2, smoking, malignan-
cies, hyperfibrinogenaemia and age. Follow-up exam-
inations were performed in 306 patients after 1–31
months (average 8 months). Two hundred and seven
healthy volunteers (34% male, 66% women, average
age 32 years) who were recruited among the employ-
ees of the University of Cologne served as a control
group. In these individuals a genetic analysis was
performed as described above. Statistical analysis was
performed using SSPS statistical package, version 8.0
by SSPS Inc, Chicago, USA. To describe differences
between non-parametric parameters chi-squared or
Fisher’s exact test were used. Significance was
regarded as p!0.05.ResultsPrevalence of APC-R
APC-R was found in 33 of 311 patients with arterial
diseases (11%). In 12 patients a genetic analysis was
added which revealed 11 heterozygote and one
homozygote Factor-V mutation. Sixteen out of 207
healthy controls showed an APC-R (8%). InTable 1. Performed procedures
Type of intervention N %
Bypass 82 26.4
Embolectomy 4 1.3
DesobliterationCpatchplasty 71 22.8
Endoluminal treatment 47 15.1
Aneurysm repair 42 13.5
Thrombolysis 10 3.2
Amputation 4 1.3
None 51 16.4
Total 311 100comparison to the study group this difference was
not significantly (pZ0.272). APC-R was equally dis-
tributed between male (25/228Z11%) and female
(8/83Z10%) patients. APC-R affected 12% of the
patients with PAOD (28/240) and 7% (5/71) of those
presenting with an AAA (pZ0.266). Twenty-one
patients presented with an occluded previously
implanted bypass, of which three had APC-R (14%).
Among the remaining 290 patients 30 had APC-R
(10%) (pZ0.476).Postoperative–postinterventional course
In 51 patients medical therapy was continued. Two
hundred and sixty patients underwent surgical or
endoluminal treatment, which was complicated by
early thrombosis in five. The overall postoperative
arterial thrombosis rate was 2% (5/231) and they all
occurred in patients without APC-R. The five throm-
botic complications all occurred after bypass oper-
ations (Table 2) resulting in a frequency of 6% in this
subgroup. Twenty-nine other treated patients with
APC-R did not show such complications. All bypass
occlusions occurred in the early postoperative course
(1st–13th day, mean 5th day). In four of the five cases
an autologous bypass had been implanted (three
femoro-infrageniculate bypasses, one aorto-femoral
bypass for infectious reason). In one patient a
femoro-suprageniculate PTFE graft occluded. None
of the patients who experienced a bypass occlusion
were immobilized preoperatively or suffered from
trauma. Bypass occlusions did not occur more
frequently in patients who were obese or who smoked.
One out of 12 patients who had malignant disease
suffered from bypass occlusion, but did not have
APC-R.
Serum level of fibrinogen was elevated (O3.5 g/l)
in 210 patients of whom 151 were also smokers. Only
two developed an arterial thrombosis. In these
patients APC-R could not be found.Follow-up
During follow-up 301 patients were examined of
which 257 had undergone surgery or endovascular
treatment. Sixteen of these patients experienced an
arterial or graft thrombosis (6%), of which two had
APC-R (pZ0.699). All incidences of thrombosis
occurred in patients with PAOD and with an infra-
geniculate distal anastomosis within 1–24 months after
the intervention (mean 1 month).Eur J Vasc Endovasc Surg Vol 30, August 2005
Table 2. Characteristics of 82 bypass procedures
Type of bypass Dacron PTFE Vein Composite Total
Aorto-iliac 5 1 – – 6 (7%)
Aorto-femoral 28 1 1 – 30 (37%)
Femoro-femoral 3 3 – – 6 (7%)
Femoro-supragen-
ual
3 9 9 – 21 (26%)
Femoro-infragenual – 3 8 2 13 (16%)
Femoro-crural – – 5 1 6 (7%)
Total 39 (48%) 17 (21%) 23 (28%) 3 (3%) 82 (100%)
M. Aleksic et al.162DiscussionAPC-R in the general population
APC-R based on Factor V-Leiden mutation is the most
important hereditary factor in the etiology of venous
thrombosis.14–16 In the normal population APC-R
occurs less frequently, but with a geographical
distribution. In the present study the prevalence of
APC-R in healthy volunteers was found to be 8%. This
figure is comparable to other epidemiological studies
performed in Germany.17 However, in Sweden and
Greece for example a prevalence of more than 10% is
documented whereas in other European regions
(France, UK, Spain, Italy) it is approximately, 3%.18
Moreover, racial differences have been shown. In the
USA APC-R varies between the black and white
population substantially (1.4 vs 5.4%). Interestingly,
this kind of thrombophilia is practically unknown in
Africa, China and Australia,19 and the reason for that
is obscure, but it is argued that all individuals
exhibiting APC-R descend from a common ancestor.20
Furthermore, APC-R represents a selection advantage
in human evolution since it protects the affected
person from major blood loss, in particular under
gynaecological or obstetrical circumstances.21 Lind-
quist22 reports that women with APC-R have a
reduced risk of bleeding during pregnancy when
compared with women without this genetic defect.APC-R in arterial diseases
The prevalence of APC-R among patients with arterial
disorders is unclear. Some authors state an increase
incidence in younger patients,23,24 suffering from
myocardial infarctions, strokes or other arterial
thrombosis.25,26 Others do not support such an
association.27 We could not confirm an increased
prevalence of APC-R in patients with PAOD or
AAA. Patients with PAOD showed a slightly increased
APC-R rate in comparison to those with AAA (12 vs
7%). This trend might become clearer in larger trialsEur J Vasc Endovasc Surg Vol 30, August 2005with greater patient numbers. In this study, the
prevalence rates might have been diluted because
the study group was investigated by performing a
functional test (the APC-ratio) in contrast to a primary
genetic analysis in the control group. However, the
additional genetic test in 12 patients with a pathologi-
cal APC-ratio revealed a sensitivity and specificity rate
of 100%. As the reliability of this test is generally
supported, the presented results seem to describe true
proportions.28APC-R in previous bypass occlusion
Only three out of 21 patients who were treated for an
occluded bypass implanted in the past showed APC-
R. Two of them had undergone surgery four times. In
the third patient a bypass procedure had been
performed only once. There were even patients in
whom more than 10 operations had been performed so
far and who did not have APC-R. The relatively small
number of affected patients precludes definite con-
clusions regarding the association between previous
graft thrombosis and APC-R.APC-R in postoperative bypass occlusion and during
follow-up
As part of the perioperative anticoagulation regimen,
antiplatelet medication is continued. Postoperatively,
low molecular heparin was given routinely in a dose
double that of the standard recommendation for
venous thrombosis prophylaxis.
All graft occlusions occurred in the early post-
operative period in mainly distal bypasses using greater
saphenous vein. None of these patients were shown to
have APC-R, and these complications likely resulted
from technical faults, which are comparatively frequent
in peripheral autologous reconstructions.
The literature provides inconsistent information
regarding this topic. Whereas in some publications the
prevalence of APC-R among patients experiencing
postoperative graft occlusion is increased,29,30 others
Prevalence of APC-resistance in Vascular Patients 163were unable to detect APC-R as a definite risk factor
for bypass failure.31 We were unable to shown any
association between graft failure and APC-R, however,
the limited number of outcome events reduces the
power of our analysis. APC-R did not seem to play a
significant role in graft failure during long-term
follow-up. All occlusion occurred in infrageniculate
bypasses. The prevalence of APC-R did not differ in
patients with (12.5%) or without (11%) failure of the
arterial reconstruction during follow-up. Likewise,
only 7% (2/29) of patients with APC-R developed an
occlusion which is comparable to an occlusion rate of
6% in all other patients without APC-R (14/228).References
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